| Leuprolide Mesylate |
Emulsion |
|
|
Develop a method to characterize in vitro release |
|
|
2023/10/06 |
| Levacetylleucine |
For Suspension |
II (Paddle) |
50 |
0.1 N HCl |
900 |
5, 10, 15, 30 and 45 |
2026/01/28 |
| Levetiracetam |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Levetiracetam |
Tablet, for Suspension |
II (Paddle) |
50 |
Phosphate Buffer, pH 6.8 (degas) |
900 |
2.5, 5, 10, 15 and 20 |
2017/03/02 |
| Levetiracetam (1 g and 1.5 g) |
Tablet (Extended Release) |
III (Reciprocating Cylinder) |
15 dips/min |
Sodium acetate buffer, pH 4.5 |
900 |
1, 2, 4, 6, 8, 10 and 12 hours |
2024/11/01 |
| Levetiracetam (500 mg and 750 mg) |
Tablet (Extended Release) |
I (Basket) |
100 |
0.05 M Phosphate Buffer, pH 6.0 |
900 |
1, 2, 4, 6, 8 and 12 hours |
2009/04/02 |
| Levocarnitine |
Tablet |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Levocetirizine Dihydrochloride |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Levofloxacin |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Levoketoconazole |
Tablet |
II (Paddle) |
50 |
0.05 N HCl |
900 |
10, 20, 30, 45 and 60 |
2025/06/23 |
| Levomilnacipran HCl |
Capsule (Extended Release) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Levonorgestrel |
Tablet |
II (Paddle) |
75 |
0.1 N HCl with 0.1% SLS |
1000 |
10, 20, 30, 45, 60 and 90 |
2004/02/05 |
| Levonorgestrel |
Intrauterine Device |
|
|
Develop a method to characterize in vitro release |
|
|
2014/02/14 |
| Levorphanol Tartrate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2021/04/22 |
| Levothyroxine Sodium |
Capsule |
I (Basket) |
100 |
0.01 N HCl, pH 2.05 |
500 |
5, 10, 15, 20, 30, 45 and 60 |
2026/05/22 |
| Levothyroxine Sodium |
Tablet |
|
|
Refer to USP |
|
|
2007/07/25 |
| Lidocaine |
Patch |
Paddle over Disk (Apparatus 5) |
50 |
Acetic acid/sodium acetate buffer, pH 4.0 at 32ºC |
500 |
10, 20, 30, 60, 120 and 180 |
2007/01/03 |
| Lidocaine |
System |
VI (Cylinder) |
50 |
Diluted McIlvaine buffer solution, pH 5.5 |
900 |
60, 120, 180, 360 and 1440 |
2026/05/22 |
| Linaclotide |
Capsule |
I (Basket) |
50 |
50 mM Phosphate Buffer, pH 4.5 |
500 |
5, 10, 15, 20 and 30 |
2015/12/24 |
| Linagliptin |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |